<DOC>
	<DOCNO>NCT01117454</DOCNO>
	<brief_summary>The purpose study test whether addition oral flecainide standard therapy reduce ventricular ectopy exercise test compare placebo plus standard therapy patient Catecholaminergic Polymorphic Ventricular Tachycardia .</brief_summary>
	<brief_title>Flecainide Catecholaminergic Polymorphic Ventricular Tachycardia</brief_title>
	<detailed_description>Catecholaminergic Polymorphic Ventricular Tachycardia ( CPVT ) genetic arrhythmia syndrome characterize frequent ventricular ectopy polymorphic , classically bidirectional ventricular tachycardia physical emotional stress , also carry risk ventricular fibrillation sudden death , despite structural heart abnormality . Treatment consist beta-blockers and/or calcium channel blocker , 30 % patient require implantable cardioverter-defibrillators ( ICDs ) due recurrent symptom medical therapy . In animal model , flecainide find directly target molecular defect CPVT . In retrospective clinical study patient CPVT see improvement ventricular ectopy exercise test flecainide add standard therapy . We propose prospective trial flecainide add standard therapy CPVT patient test hypothesis flecainide reduce ventricular ectopy exercise test compare placebo plus standard therapy . This single-blind ( blinded subject ) randomize cross-over study , patient receive treatment A ( flecainide placebo ) least 3 month , 1 week wash-out , treatment B ( placebo flecainide ) least 3 month .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>1 . Clinical diagnosis CPVT , base : A. reproducible polymorphic bidirectional ventricular tachycardia exercise OR B. Ventricular ectopy exercise test RYR2 CASQ2 mutation 2 . Functioning ICD place 3 . On stable dose standard therapy define maximal tolerate dose betablocker may include calcium channel blocker Patients flecainide mexiletine also eligible enrollment 1 week `` washout '' period flecainide mexiletine discontinue , standard therapy alone use . 1 . Females pregnant plan pregnant study period 2 . Children &lt; 5 year age 3 . Patients unable perform treadmill exercise 4 . Patients significant structural heart disease 5 . Patients feature consistent AndersenTawil syndrome A . Periodic paralysis unexplained weakness B. Dysmorphic facies C. Known KCNJ2 mutation 6 . Patients know hypersensitivity flecainide 7 . Patients amiodarone 8 . Patients expect comply followup</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Catecholaminergic Polymorphic Ventricular Tachycardia</keyword>
	<keyword>implantable cardioverter-defibrillator</keyword>
	<keyword>flecainide</keyword>
</DOC>